BR112021021244A2 - Inibidores glicomiméticos multiméricos ligados à galactose de receptores de e-selectinas, galectina-3 e/ou quimiocina cxcr4 - Google Patents

Inibidores glicomiméticos multiméricos ligados à galactose de receptores de e-selectinas, galectina-3 e/ou quimiocina cxcr4

Info

Publication number
BR112021021244A2
BR112021021244A2 BR112021021244A BR112021021244A BR112021021244A2 BR 112021021244 A2 BR112021021244 A2 BR 112021021244A2 BR 112021021244 A BR112021021244 A BR 112021021244A BR 112021021244 A BR112021021244 A BR 112021021244A BR 112021021244 A2 BR112021021244 A2 BR 112021021244A2
Authority
BR
Brazil
Prior art keywords
galectin
selectin
cxcr4 chemokine
galactose
chemokine receptors
Prior art date
Application number
BR112021021244A
Other languages
English (en)
Portuguese (pt)
Inventor
K Sarkar Arun
Hong-Woon Yang
L Magnani John
M Peterson John
Myung-Gi Baek
U Vohra Yusufbhai
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Publication of BR112021021244A2 publication Critical patent/BR112021021244A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BR112021021244A 2019-04-24 2020-04-21 Inibidores glicomiméticos multiméricos ligados à galactose de receptores de e-selectinas, galectina-3 e/ou quimiocina cxcr4 BR112021021244A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838206P 2019-04-24 2019-04-24
PCT/US2020/029066 WO2020219417A1 (en) 2019-04-24 2020-04-21 Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors

Publications (1)

Publication Number Publication Date
BR112021021244A2 true BR112021021244A2 (pt) 2021-12-21

Family

ID=70680623

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021244A BR112021021244A2 (pt) 2019-04-24 2020-04-21 Inibidores glicomiméticos multiméricos ligados à galactose de receptores de e-selectinas, galectina-3 e/ou quimiocina cxcr4

Country Status (9)

Country Link
US (1) US20230079833A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958978A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022529806A (cg-RX-API-DMAC7.html)
KR (1) KR20220012246A (cg-RX-API-DMAC7.html)
CN (1) CN114340736A (cg-RX-API-DMAC7.html)
AU (1) AU2020263266A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021021244A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136661A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020219417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7547345B2 (ja) 2018-12-27 2024-09-09 グリコミメティクス, インコーポレイテッド ガレクチン-3阻害性c-グリコシド
ES3063748T3 (en) * 2019-07-31 2026-04-20 Crescent Biopharma Inc E-selectin antagonists for use in enhancing the survival of reconstituted, bone marrow-depleted hosts
US20230147312A1 (en) 2020-03-27 2023-05-11 Glycomimetics, Inc. Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin
WO2021247396A1 (en) 2020-05-31 2021-12-09 Magnani John L Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis
JP2023529485A (ja) 2020-06-14 2023-07-10 グリコミメティクス, インコーポレイテッド E-セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法
WO2023014690A1 (en) 2021-08-03 2023-02-09 Glycomimetics, Inc. Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス, インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SI2264043T1 (en) 2005-09-02 2018-01-31 Glycomimetics, Inc. HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS
US7964569B2 (en) 2006-10-12 2011-06-21 Glycomimetics, Inc. Glycomimetic replacements for hexoses and N-acetyl hexosamines
US8697862B2 (en) 2008-05-16 2014-04-15 Galecto Biotech Ab Synthesis of galactoside inhibitors
EP2794626B3 (en) 2011-12-22 2020-08-05 GlycoMimetics, Inc. E-selectin antagonist compounds
CA2888527A1 (en) * 2012-10-31 2014-05-08 Glycomimetics, Inc. E-selectin antagonists compounds and methods of use
CN107108679B (zh) 2014-12-03 2020-10-23 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
BR112019006642A2 (pt) * 2016-10-07 2019-07-02 Glycomimetics Inc antagonistas multiméricos de e-selectina altamente potentes

Also Published As

Publication number Publication date
CN114340736A (zh) 2022-04-12
JP2022529806A (ja) 2022-06-24
US20230079833A1 (en) 2023-03-16
WO2020219417A1 (en) 2020-10-29
KR20220012246A (ko) 2022-02-03
AU2020263266A1 (en) 2021-12-16
EP3958978A1 (en) 2022-03-02
CA3136661A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
EA202190377A9 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
MX2025007468A (es) Composiciones y metodos para el manejo de trastornos
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
BR112022000328A2 (pt) Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BR112019016497A2 (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer.
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
UY31619A1 (es) Compuestos espiro como antagonistas del receptor npy y5
BRPI0514553A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
UY39522A (es) Anticuerpos de cadena pesada que se unen al receptor alfa de folato
CL2024002612A1 (es) Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso.
CO2023012684A2 (es) Compuestos agonistas beta del receptor de la hormona tiroidea
BR112022017822A2 (pt) Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
BR112022004461A2 (pt) Conjugado de galnac-oligonucleotídeo para entrega ao fígado e método de fabricação do mesmo
BR112023021225A2 (pt) Anticorpos anti-cd20 e estruturas t car
WO2024227174A3 (en) Antibodies that bind ox40l and methods of use
CL2018003044A1 (es) 6-aminopiridina-3-yl tiazoles como moduladores de ror.
MX2024010344A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
CL2024000370A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX2024005430A (es) Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
BR112018014525A2 (pt) compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
BR112019003406A2 (pt) antagonistas do receptor androgênico tio-hidantoína para o tratamento de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2876 DE 18/02/2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 17, DA PORTARIA 52/2023.